II Amendment

In the Claims:

Applicants had previously canceled claims 1–27, 50, 53 and 77. Applicants cancel withdrawn claims 28-49, 51–52 and 78–112. Applicants amend claims 54–76 as set forth below in a complete listing of the claims of the Application, with the status of each claim indicated:

Claims 1–53. (canceled)

Claim 54. (currently amended) An injectable aqueous medicinal solution comprising (i) at least one pharmaceutically active ingredient and (ii) colloid-forming macromolecules selected from the group consisting of polysaccharides, ~~or modified~~ substituted polysaccharides, polypeptides, ~~modified~~ substituted polypeptides and albumins, ~~characterized in that~~ wherein said pharmaceutically active ingredients are selected from the group consisting of slimming preparations/anorexiants, acidose therapeutics, amino acids (*e.g.*, histidine) or modified amino acids, analeptics/antihypoxemics, analgetics/antirheumatics, anthelmintics, antiallergics, antianemics, antiarrhythmics, antibiotics/antiinfectives, antidementives (nootropics), antidiabetics, antidotes, antiemetics/antivertiginosics, antiepileptics, antihemorrhagics (antifibrinolytics and other hemostatics), antihypertensives, antihypoglycemics, antihypotensives, anticoagulants, antimycotics, antiparasitics (internal), antiphlogistics, antitussives/expectorants, anti-arteriosclerosis agents, balneotherapeutics and agents for heat therapy, beta receptor and calcium channel blockers and inhibitors of the renin-angiotensin system, broncholytics/antiasthmatics, cholagogics and bile duct

therapeutics, cholinergics, corticoids (internal), dermatics (internal), dietetics/nutrition therapeutics, diagnostics and agents for diagnostic preliminaries, diuretics, agents stimulating blood flow, withdrawal agents, enzyme inhibitors, enzyme preparations and transport proteins, fibrinolytics, geriatric agents, gout agents, influenza remedies, gynecologic agents, anti-hemorrhoidal agents (proctologics), hepatics, hypnotics/sedatives, hypophysis and hypothalamus hormones, regulatory peptides and their inhibitors, immunotherapeutics and cytokines, infusion and standard injection solutions, organ perfusion solutions, cardiacs, anti-caries and anti-paradontosis agents and other dental preparations, coronary agents, laxants, lipid depressants, neural therapeutics, gastro-intestinal agents, migraine remedies, mineral preparations, muscle relaxants, narcotics, parathyroid hormones/calcium-metabolic regulators/osteoporosis remedies, neuropathy preparations and other neurotropic agents, neurotransmitters (*e.g.*, dopamine) or modified neurotransmitters, ophthalmics, otologics, ~~Parkinson remedies and other remedies against extrapyramidal disturbances~~ Parkinson's and other degenerative diseases, psychopharmacons, sinusitis remedies, roborants/tonics, thyroid therapeutics, serums, immunoglobulins and vaccines, sexual hormones and their inhibitors, spasmolytics, platelet aggregation inhibitors, tuberculosis remedies, alterants, urologic agents, vein therapeutics, vitamins, wound treatment agents, cytostatics and metastasis inhibitors.

Claim 55. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said polysaccharide is selected from the group consisting of cellulose, starch and dextrane.

Claim 56. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said modified polysaccharide is hydroxyethylstarch ~~[poly(O-hydroxyethyl)starch]~~.

Claim 57. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said hydroxyethylstarch has a degree of substitution, DS, of < 0.4.

Claim 58. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said hydroxyethylstarch has an average molecular weight of below 300,000.

Claim 59. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said hydroxyethylstarch has an average molecular weight of below 70,000.

Claim 60. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said hydroxyethylstarch has a degree of substitution, DS, of < 0.4 and an average molecular weight of below 300,000.

Claim 61. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that the dextrane has an average molecular weight of below 40,000.

Claim 62. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that the dextrane has an average molecular weight of below 15,000.

Claim 63. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that gelatin is employed as said polypeptide.

Claim 64. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that oxypolygelatin or gelatin succinate is employed as said modified polypeptide.

Claim 65. (currently amended) The injectable aqueous medicinal solution according to claim ~~64~~ 70, characterized in that said oxypolygelatin and gelatin succinate have an average molecular weight of below 40,000.

Claim 66. (currently amended) The injectable aqueous medicinal solution according to claim ~~64~~ 70, characterized in that said oxypolygelatin and gelatin succinate have an average molecular weight of below 15,000.

Claim 67. (currently amended) The injectable aqueous medicinal solution according to claim ~~63~~ 70, characterized in that said albumins are selected from the group consisting of human albumin, cleavage products of albumin, and recombinant human serum albumin.

Claim 68. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said colloid-forming macromolecules have a colloid-osmotic pressure in aqueous solution of > 1333 Pa (10 mm Hg).

Claim 69. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said colloid-forming macromolecules have a colloid-osmotic pressure in aqueous solution of > 3733 Pa (28 mm Hg).

Claim 70. (currently amended) ~~The~~ An injectable aqueous medicinal solution ~~according to claim 55, characterized in that the proportion of the colloid-forming macromolecules is~~ comprising (i) at least one pharmaceutically active ingredient and (ii) from 2 to 25% by weight, based on the total amount of the injectable aqueous solution of colloid-forming macromolecules selected from the group consisting of polysaccharides, substituted polysaccharides, polypeptides, substituted polypeptides and albumins, wherein said pharmaceutically active ingredients are (i) selected from the group consisting of slimming preparations/anorexiants, acidose therapeutics, amino acids (*e.g.*, histidine) or modified amino acids, analeptics/ antihypoxemics, analgetics/antirheumatics, antihelmintics, antiallergics, antianemics, antiarrhythmics, antibiotics/antiinfectives, antidementives

(nootropics), antidiabetics, antidotes, antiemetics/antivertiginosics, antiepileptics, antihemorrhagics (antifibrinolytics and other hemostatics), antihypertensives, antihypoglycemics, antihypotensives, anticoagulants, antimycotics, antiparaasitics (internal), antiphlogistics, antitussives/expectorants, anti-arteriosclerosis agents, balneotherapeutics and agents for heat therapy, beta receptor and calcium channel blockers and inhibitors of the renin-angiotensin system, broncholytics/ antiassthmatics, cholagogics and bile duct therapeutics, cholinergics, corticoids (internal), dermatics (internal), dietetics/nutrition therapeutics, diagnostics and agents for diagnostic preliminaries, diuretics, agents stimulating blood flow, withdrawal agents, enzyme inhibitors, enzyme preparations and transport proteins, fibrinolytics, geriatric agents, gout agents, influenza remedies, gynecologic agents, anti-hemorrhoidal agents (proctologics), hepatics, hypnotics/sedatives, hypophysis and hypothalamus hormones, regulatory peptides and their inhibitors, immunotherapeutics and cytokines, infusion and standard injection solutions, organ perfusion solutions, cardiacs, anti-caries and anti-paradontosis agents and other dental preparations, coronary agents, laxants, lipid depressants, neural therapeutics, gastro-intestinal agents, migraine remedies, mineral preparations, muscle relaxants, narcotics, parathyroid hormones/calcium-metabolic regulators/osteoporosis remedies, neuropathy preparations and other neurotropic agents, neurotransmitters (*e.g.*, dopamine) or modified neurotransmitters, ophthalmics, otologics, Parkinson's and other degenerative diseases, psychopharmacons, sinusitis remedies, roborants/tonics, thyroid therapeutics, serums, immunoglobulins and vaccines, sexual hormones and their inhibitors, smasmolytics, platelet aggregation inhibitors, tuberculosis

remedies, alterants, urologic agents, vein therapeutics, vitamins, wound treatment agents, cytostatics and metastasis inhibitors.

Claim 71. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that the proportion of the colloid-forming macromolecules is from 3 to 15% by weight, based on the total amount of the injectable aqueous solution.

Claim 72. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said injectable aqueous solution additionally has a cation proportion of from 100 to 170 mmol/l and an anion proportion of from 100 to 170 mmol/l.

Claim 73. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said injectable aqueous solution additionally has a cation proportion of from 100 to 150 mmol/l and an anion proportion of from 100 to 150 mmol/l.

Claim 74. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that part of the cation and/or anion concentration is replaced by a natural or synthetic polyol.

Claim 75. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said injectable aqueous solution has an osmolarity of between 250 and 400 mOsmol/l.

Claim 76. (currently amended) The injectable aqueous medicinal solution according to claim ~~54~~ 70, characterized in that said pharmaceutically active ingredient is contained in a proportion of from 0.5 to 25% by weight, based on the total amount of the injectable aqueous solution.

Claims 77–112. (canceled)